27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
The Vetr crowd on Thursday upgraded its rating for GlaxoSmithKline plc (ADR) (NYSE:GSK) from 3 stars (Hold), issued 527 days ago, to 4 stars (Buy). Crowd sentiment at the time of the upgrade was mostly positive, with 80 percent of Vetr user ratings bullish.
Share price in GSK took a pronounced downturn throughout April, in part due to the company's recall of 600,000 defective inhalers that occasionally failed in delivering the correct amount of medication per use.
GSK's stock has fallen more than 2.5 percent since the beginning of the month and was recently trading around $40.80.
Learn how crowdsourced ratings could help you time the market.
Currently, the Vetr crowd's average target price for GlaxoSmithKline is up at $45.30, which is still just below the average analyst target price of $45.67. Less than 2 percent of Vetr users are holding GSK in their watch lists.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!